|
|
|
Journalists
Press releases
Press releases 2009
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Press releases are intended to journalists, analysts and investors.
FDA licenses new influenza vaccine designed specifically for people 65 years of age and older
December 23, 2009
Sanofi-aventis to acquire Chattem Inc. creating a strong U.S. Consumer Healthcare platform
December 21, 2009
Sanofi-aventis provides an R&D Pipeline update
December 21, 2009
Sanofi-aventis Board of Directors of December 16, 2009
December 16, 2009
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
December 16, 2009
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
December 15, 2009
BiPar Sciences Announces Update on the Clinical Development Progress of BSI-201 for Metastatic Triple-Negative Breast Cancer
December 11, 2009
Sanofi-aventis doubles syringe production capacity and diversifies vaccine production at the Le Trait Manufacturing Plant
December 11, 2009
Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
December 10, 2009
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
December 9, 2009
Sanofi-aventis establishes strategic research alliance with California Institute of Technology
December 9, 2009
Sanofi-aventis enters into an exclusive global licensing agreement with The Rockefeller University
December 3, 2009
Multaq® Approved in the European Union for patients with atrial fibrillation
November 30, 2009
Sanofi-aventis confirms its intent to reinforce its presence in the Russian Federation via the “Pharmpolis Project”
November 27, 2009
Sanofi-aventis and Medicines for Malaria Venture to launch the largest ever study of an antimalarial drug
November 19, 2009
Sanofi-aventis launches major new registry including over 10,000 patients worldwide with atrial fibrillation
November 16, 2009
Panenza®, Sanofi Pasteur’s Influenza A(H1N1) 2009 vaccine, approved in France
November 16, 2009
Sanofi-aventis and Regeneron expand strategic antibody collaboration
November 10, 2009
Sanofi-aventis announces changes to Executive Committee
November 2, 2009
Sanofi-aventis delivers a solid performance in third quarter 2009
October 30, 2009
Sanofi-aventis to acquire Oenobiol, French leader in nutritional beauty supplements
October 30, 2009
Sanofi-aventis and US biopharmaceutical company Micromet sign global collaboration and license agreement for new solid tumor BiTE antibody
October 29, 2009
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
October 21, 2009
Merial invests US $ 70 million in Nanchang, China
October 12, 2009
Panenza®* and Humenza®* Influenza A(H1N1) Vaccines Demonstrate Robust Immune Response After One Dose
October 8, 2009
Sanofi Pasteur and the Alliance for Rabies Control enter into a global partnership
October 2, 2009
Sanofi Pasteur announces results of U.S. clinical trials in adults following one dose of influenza A (H1N1) vaccine
October 1, 2009
Sanofi-aventis successfully completes the placement of 5-year and 10-year Euro notes issues for an aggregate principal amount of EUR 1.5 billion
October 1, 2009
Sanofi-aventis to acquire FOVEA, a French biopharmaceutical ophthalmology company
October 1, 2009
Sanofi-aventis and U.S. Biotechnology company Merrimack enter into an Exclusive Global Collaboration and Licensing Agreement for a monoclonal antibody in Oncology
October 1, 2009
ClikSTAR® a new reusable insulin pen for use with Lantus® and Apidra® approved in EU and Canada
September 30, 2009
Superior efficacy-dose ratio for Lantus® over detemir
September 30, 2009
Two new meta-analyses confirm once-daily Lantus® efficacy and reduced risk of hypoglycaemia compared to NPH Insulin
September 30, 2009
Sanofi-aventis launches major insulin research program in partnership with the international scientific community
September 29, 2009
Sanofi-aventis announces dismissal of U.S. securities law suit regarding Zimulti® (rimonabant)
September 28, 2009
Multaq® (dronedarone) Recommended for Approval in the European Union
September 25, 2009
Sanofi Pasteur Commends Results of First HIV Vaccine Study to Show Some Effectiveness in Preventing HIV
September 24, 2009
Sanofi Pasteur Receives Additional Order from U.S. Government to Produce Influenza A (H1N1) Vaccine
September 21, 2009
Sanofi-aventis receives renewed recognition as a leader in sustainability
September 21, 2009
Sanofi-aventis completes Acquisition of Merck's Interest in Merial
September 18, 2009
Sanofi-aventis Receives Complete Response Letter from the FDA for Eplivanserin (Ciltyri®) Submission
September 16, 2009
U.S. FDA Licenses Sanofi Pasteur’s Pandemic Influenza Vaccine
September 15, 2009
Roberto Pucci appointed Senior Vice President, Human Resources
September 15, 2009
Gilles Lhernould appointed Senior Vice President Corporate Social Responsibility
September 15, 2009
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
September 11, 2009
Encouraging phase II results with teriflunomide in patients with relapsing multiple sclerosis
September 11, 2009
Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government
September 7, 2009
Shantha Biotechnics awarded large vaccine contracts by United Nations agency
September 1, 2009
Study Shows Otamixaban substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
August 30, 2009
New large-scale, global study provides additional information about an intensified dose-regimen of Plavix® in acute coronary syndrome patients undergoing angioplasty
August 30, 2009
Multaq® (dronedarone) for Atrial Fibrillation Now Approved in Canada
August 12, 2009
Sanofi Pasteur submits supplemental application for A(H1N1) pandemic vaccine to U.S. FDA
August 7, 2009
Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer
August 5, 2009
The Foundation for the National Institutes of Health and sanofi-aventis announce unprecedented product donation by sanofi-aventis in the United States.
August 5, 2009
Availability on line of the Group’s half-year financial report for 2009
July 30, 2009
Sanofi-aventis to Acquire Merck's Interest in Merial
July 30, 2009
Very good second quarter 2009: Increase in 2009 guidance
July 29, 2009
Multaq® (dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States
July 28, 2009
Sanofi Pasteur strengthens vaccines position in India through the control of Shantha Biotechnics via Mérieux Alliance
July 27, 2009
Sanofi-aventis welcomes the European Medicines Agency’s statement on Lantus® safety
July 23, 2009
BSI-201 enters phase III in metastatic triple negative breast cancer
July 17, 2009
Sanofi Pasteur receives order from French Government to produce novel influenza A(H1N1) vaccine
July 16, 2009
Expert Statement issued about Lantus® following recent publications in Diabetologia
July 15, 2009
5-year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus® Compared to NPH
July 6, 2009
FDA Approves Multaq® for Patients with Atrial Fibrillation or Atrial Flutter
July 2, 2009
International Mobilization to Fight Against Childhood Cancer in Low- and Middle- Income Countries
July 1, 2009
Sanofi-aventis presents New R&D Model Project to boost Innovation
June 30, 2009
Christian Lajoux appointed President for sanofi-aventis in France
June 29, 2009
Sanofi-aventis stands behind the safety of Lantus®
June 26, 2009
Update on Eloxatin® (oxaliplatin) U.S. Patent Litigation
June 18, 2009
Call for Common Action to Fight the Influenza Pandemic
June 17, 2009
Sanofi Pasteur Ready to Support Public Health Efforts in Response to WHO Phase 6 Influenza Pandemic Alert
June 11, 2009
Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer with Recurrent Symptomatic Malignant Ascites
June 11, 2009
Sanofi-aventis to purchase Diabel manufacturing facility in Frankfurt to strengthen Insulin Production Capacities
June 8, 2009
Jean-Philippe Santoni appointed Senior Vice President, Industrial Development and Innovation
June 8, 2009
Laure Thibaud appointed Senior Vice President, Communications, sanofi-aventis
June 2, 2009
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
May 31, 2009
Update on Clopidogrel centralized applications in the European Union
May 29, 2009
Sanofi-aventis and Biotechnology company Exelixis enter into an Exclusive Global Alliance for Novel Targeted Oncology Therapies
May 28, 2009
Sanofi Pasteur Receives Seed Virus to Produce new Influenza A(H1N1) Vaccine
May 27, 2009
Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine
May 25, 2009
Sanofi-aventis and DNDi enter into a Collaboration Agreement on a New Drug for Sleeping Sickness, Fexinidazole
May 18, 2009
Sanofi-aventis introduces sanofi-aventis TV « A window on our company »
May 15, 2009
Sanofi-aventis and Kyowa Hakko Kirin enter into a Collaboration and Licensing Agreement on an Anti LIGHT fully human monoclonal antibody
May 14, 2009
Sanofi-aventis builds a New Vaccine Manufacturing Facility in France with an investment of 350 million euros
May 12, 2009
U.S. FDA Licenses Sanofi Pasteur’s New Influenza Vaccine Manufacturing Facility
May 6, 2009
Sanofi-aventis has successfully completed the placement of a 4-year and a 7-year Euro notes issue for an aggregate principal amount of EUR 3 billion
May 6, 2009
Sanofi-aventis converts its Vitry-sur-Seine Industrial facility to biotechnologies
May 5, 2009
Sanofi-aventis supports public health efforts against new influenza A/H1N1 virus
April 29, 2009
Good first-quarter 2009 performance
April 29, 2009
Sanofi-aventis Donates Medical Equipment to Zundao Community Hospital
April 22, 2009
Sanofi-aventis Builds New Manufacturing Base in Hangzhou
April 21, 2009
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded to Singapore and Vietnam
April 21, 2009
Sanofi-aventis Announces New Investment in China to Locally Produce Lantus® SoloSTAR®
April 21, 2009
Sanofi-aventis Combined General Meeting of April 17, 2009
April 17, 2009
Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company
April 15, 2009
Sanofi-aventis to Acquire Medley in Brazil
April 9, 2009
Sanofi-aventis acquires Laboratorios Kendrick in Mexico
April 2, 2009
Plavix® plus Aspirin more effective than Aspirin alone in preventing major vascular events in patients with Atrial Fibrillation who cannot take oral anticoagulants
March 31, 2009
EMERFLU®, pandemic influenza vaccine for humans, approved in Australia
March 26, 2009
Sanofi-aventis Combined General Meeting of April 17, 2009
March 23, 2009
FDA Advisory Committee recommends Approval of Multaq® (dronedarone)
March 18, 2009
Sanofi-aventis announces final results of Zentiva Offer
March 12, 2009
Investor Advisory on Mini-Tender Offers
March 11, 2009
Sanofi-aventis invests €100 million in new facility in Mexico to produce seasonal and pandemic influenza vaccine
March 9, 2009
Jérôme Contamine appointed Chief Financial Officer
March 9, 2009
Filing of the 2008 U.S. Form 20-F and French “Document de Référence” and Annual Financial Report
March 5, 2009
INTANZA®/IDflu®, first intradermal influenza vaccine, approved in the European Union
February 26, 2009
FDA approves Apidra® SoloSTAR® a pre-filled disposable insulin pen
February 26, 2009
Steve Oldfield appointed General Manager, sanofi-aventis UK
February 25, 2009
Sanofi-aventis announces success of Zentiva Offer
February 25, 2009
Sanofi-aventis and the Salk Institute establish regenerative medicine research alliance
February 24, 2009
Sanofi-aventis U.S Chairman Tim Rothwell to retire after an Outstanding Career
February 24, 2009
Sanofi Pasteur dengue vaccine enters pediatric efficacy clinical study
February 18, 2009
Sanofi Pasteur starts a phase II study of a vaccine against Clostridium difficile
February 17, 2009
New England Journal of Medicine publishes results from the landmark ATHENA trial with Multaq® (dronedarone) in Atrial Fibrillation
February 11, 2009
Sanofi-aventis delivers 2008 Results above Guidance
February 11, 2009
Laurence Debroux appointed Chief Strategic Officer (CSO)
February 11, 2009
Elias Zerhouni, Scientific Advisor to the Chief Executive Officer
February 11, 2009
Jean-Pierre Lehner appointed Chief Medical Officer
February 11, 2009
European Commission clears acquisition of Zentiva NV by sanofi-aventis
February 4, 2009
|
|
